
Coronary Artery Disease - Pipeline Insight, 2025
Description
DelveInsight’s, “Coronary Artery Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Coronary Artery Disease: Overview
Coronary artery disease is a common heart condition. Coronary artery disease may also be called coronary heart disease. The major blood vessels that supply the heart (coronary arteries) struggle to send enough blood, oxygen and nutrients to the heart muscle. Cholesterol deposits (plaques) in the heart arteries and inflammation are usually the cause of coronary artery disease.
Signs and symptoms of coronary artery disease occur when the heart doesn't get enough oxygen-rich blood. If you have coronary artery disease, reduced blood flow to the heart can cause chest pain (angina) and shortness of breath. A complete blockage of blood flow can cause a heart attack. Coronary artery disease often develops over decades. Symptoms may go unnoticed until a significant blockage causes problems or a heart attack occurs.
""Coronary Artery Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Coronary Artery Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Coronary Artery Disease Emerging Drugs
Further product details are provided in the report……..
Coronary Artery Disease: Therapeutic Assessment
This segment of the report provides insights about the different Coronary Artery Disease drugs segregated based on following parameters that define the scope of the report, such as:
Coronary Artery Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Coronary Artery Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronary Artery Disease drugs.
Coronary Artery Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Coronary Artery Disease: Overview
Coronary artery disease is a common heart condition. Coronary artery disease may also be called coronary heart disease. The major blood vessels that supply the heart (coronary arteries) struggle to send enough blood, oxygen and nutrients to the heart muscle. Cholesterol deposits (plaques) in the heart arteries and inflammation are usually the cause of coronary artery disease.
Signs and symptoms of coronary artery disease occur when the heart doesn't get enough oxygen-rich blood. If you have coronary artery disease, reduced blood flow to the heart can cause chest pain (angina) and shortness of breath. A complete blockage of blood flow can cause a heart attack. Coronary artery disease often develops over decades. Symptoms may go unnoticed until a significant blockage causes problems or a heart attack occurs.
""Coronary Artery Disease - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Coronary Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve Coronary Artery Disease.
This segment of the Coronary Artery Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Coronary Artery Disease Emerging Drugs
- Flurpiridaz F-18: GE Healthcare
- Evolocumab: Amgen
- Revacept: advanceCor
Further product details are provided in the report……..
Coronary Artery Disease: Therapeutic Assessment
This segment of the report provides insights about the different Coronary Artery Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Coronary Artery Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Coronary Artery Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Coronary Artery Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronary Artery Disease drugs.
Coronary Artery Disease Report Insights
- Coronary Artery Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Coronary Artery Disease drugs?
- How many Coronary Artery Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Coronary Artery Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Coronary Artery Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Coronary Artery Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis Pharmaceuticals
- Amgen
- Imbria Pharmaceuticals, Inc.
- AstraZeneca
- Jiangsu Vcare Pharmatech
- GE Healthcare
- Flurpiridaz F18
- Evolocumab
- Inclisiran
- Ninerafaxstat
- MEDI6570
- Vicagrel
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Coronary Artery Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Coronary Artery Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Evolocumab: Amgen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Ninerafaxstat: Imbria Pharmaceuticals, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Coronary Artery Disease Key Companies
- Coronary Artery Disease Key Products
- Coronary Artery Disease- Unmet Needs
- Coronary Artery Disease- Market Drivers and Barriers
- Coronary Artery Disease- Future Perspectives and Conclusion
- Coronary Artery Disease Analyst Views
- Coronary Artery Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.